华东医药: 关于全资子公司签署产品独家商业化合作协议的公告

Transaction Overview - East China Pharmaceutical's subsidiary, East China Pharmaceutical (Hangzhou), has entered into an exclusive commercialization agreement with Jiangsu Weikail Pharmaceutical Technology Co., Ltd. for the oral formulation VC005 in mainland China [1][4] - The agreement includes an upfront payment of 50 million RMB and milestone payments not exceeding 180 million RMB [1][5] Company Profiles - Jiangsu Weikail, established in 2010, focuses on innovative drug development and has a robust pipeline with five clinical projects and several preclinical projects targeting various diseases [2][3] - East China Pharmaceutical (Hangzhou) is a wholly-owned subsidiary of East China Pharmaceutical, primarily engaged in the wholesale and retail of pharmaceutical products and medical devices [1] Product Details - VC005 is a novel, highly selective second-generation oral JAK1 inhibitor, currently in clinical development for several autoimmune diseases, including moderate to severe atopic dermatitis and ankylosing spondylitis [3][4][8] - The product has shown comparable efficacy to existing treatments and is expected to address safety concerns associated with excessive JAK2 inhibition [4][8] Agreement Terms - East China Pharmaceutical (Hangzhou) will act as the exclusive distributor for VC005 in the designated region, while Jiangsu Weikail retains responsibility for the product's research, registration, production, and supply [4][5] - The agreement allows for the potential transfer of marketing authorization rights under certain conditions, with East China Pharmaceutical (Hangzhou) holding priority rights [5] Market Implications - The collaboration aims to meet the unmet clinical needs in the autoimmune disease treatment space, particularly for atopic dermatitis and vitiligo, which have significant patient populations and treatment challenges [6][7][9] - VC005's oral formulation is expected to enhance patient compliance and accessibility, positioning it as a leading treatment option in the autoimmune disease market [8][9] Future Plans - The company plans to continue focusing on clinical needs and patient outcomes while collaborating with domestic and international firms to advance its drug development and commercialization efforts [10]